In a Phase IIb trial (NCT04641299), a single subcutaneous dose of 90 mg AZD8233 effectively reduced PCSK9 by more than 90%, with a maximum average reduction of nearly 70% in LDL-C levels in patients with dyslipidemia. Here, PCSK9 is linked to metabolic syndrome.